BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korangy F, Höchst B, Manns MP, Greten TF. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010;4:345-53. [PMID: 20528121 DOI: 10.1586/egh.10.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology 2017;7:e1372079. [PMID: 29296523 DOI: 10.1080/2162402X.2017.1372079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
2 Ilan Y. Immune therapy for hepatocellular carcinoma. Hepatol Int 2014;8 Suppl 2:499-504. [PMID: 26201331 DOI: 10.1007/s12072-013-9501-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. 2018;67:1305-1315. [PMID: 29959458 DOI: 10.1007/s00262-018-2190-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
4 Zhao F, Hoechst B, Gamrekelashvili J, Ormandy LA, Voigtländer T, Wedemeyer H, Ylaya K, Wang XW, Hewitt SM, Manns MP, Korangy F, Greten TF. Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol 2012;188:6055-62. [PMID: 22615204 DOI: 10.4049/jimmunol.1102918] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
5 Kitahara M, Mizukoshi E, Nakamoto Y, Mukaida N, Matsushima K, Kaneko S. Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus-related hepatocellular carcinoma. Int Immunopharmacol 2014;21:346-53. [PMID: 24893118 DOI: 10.1016/j.intimp.2014.05.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Lee I, Huang Y, Chau G, Huo T, Su C, Wu J, Lin H. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments: Interferon-gamma and HCC. Int J Cancer 2013. [DOI: 10.1002/ijc.28311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
7 Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8:71002-71011. [PMID: 29050338 DOI: 10.18632/oncotarget.20238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
8 Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis. 2012;30:477-482. [PMID: 23108303 DOI: 10.1159/000341695] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
9 Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl 2011;17 Suppl 2:S147-58. [PMID: 21714065 DOI: 10.1002/lt.22367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
10 Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Büchler MW, Beckhove P, Huber PE, Weitz J. A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer 2011;11:419. [PMID: 21961577 DOI: 10.1186/1471-2407-11-419] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
11 Sengupta D, Chowdhury KD, Sarkar A, Paul S, Sadhukhan GC. Berberine and S allyl cysteine mediated amelioration of DEN+CCl4 induced hepatocarcinoma. Biochimica et Biophysica Acta (BBA) - General Subjects 2014;1840:219-44. [DOI: 10.1016/j.bbagen.2013.08.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
12 Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 2015;61:1957-67. [PMID: 25645298 DOI: 10.1002/hep.27728] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
13 Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62. [PMID: 24030703 DOI: 10.1158/1078-0432.CCR-13-1189] [Cited by in Crossref: 76] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
14 Li Y, Siegel DL, Scholler N, Kaplan DE. Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. BMC Biotechnol 2012;12:23. [PMID: 22564378 DOI: 10.1186/1472-6750-12-23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]